10-Q: Invivyd Reports Third Quarter 2024 Results, Cites Revenue Growth and Ongoing Clinical Development

Invivyd, Inc. reported its third quarter 2024 financial results, highlighting revenue from PEMGARDA sales and progress in clinical development of its next-generation antibody candidate.

Summary

• Invivyd, Inc. reported a net loss of $60.7 million for the third quarter of 2024, compared to a net loss of $39.4 million for the same period in 2023.
• The company generated $9.3 million in product revenue from sales of PEMGARDA, which received emergency use authorization (EUA) in March 2024.
• Research and development expenses increased to $57.9 million in Q3 2024 from $25.6 million in Q3 2023, primarily due to the advancement of the VYD2311 program.
• Selling, general, and administrative expenses were $13.0 million for Q3 2024, consistent with $12.9 million for Q3 2023.
• The company's cash and cash equivalents totaled $106.9 million as of September 30, 2024, down from $200.6 million at the end of 2023.
• Invivyd has concluded that there is substantial doubt about its ability to continue as a going concern based on current operating plans and excluding any contribution from future revenues or external financing.
• The company is actively pursuing additional funding through various means, including revenue generation, equity offerings, grants, debt financing, and strategic collaborations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is positive news regarding revenue generation and clinical trial progress, the significant increase in net loss, the decrease in cash reserves, and the going concern warning are major concerns. The company is facing significant financial challenges and is dependent on external funding.

Positives

• The company successfully launched PEMGARDA and generated $9.3 million in product revenue in Q3 2024.
• The company has initiated a Phase 1 clinical trial for VYD2311, a next-generation mAb candidate for COVID-19.
• Invivyd has submitted a request to the FDA to amend the EUA for PEMGARDA for treatment of COVID-19.
• The company has a repeatable immunobridging pathway with the FDA for future potential EUAs for serial, novel mAbs.
• The company has a robust safety data package from adintrevimab, which is being leveraged for new mAb candidates.

Negatives

• The company reported a net loss of $60.7 million for the third quarter of 2024, a significant increase from the $39.4 million loss in the same period of 2023.
• The company's cash and cash equivalents decreased to $106.9 million as of September 30, 2024, from $200.6 million at the end of 2023.
• Invivyd has concluded that there is substantial doubt about its ability to continue as a going concern.
• The company's operating expenses increased significantly, primarily due to research and development costs.
• The company is dependent on third-party organizations for manufacturing and processing its product candidates.

Risks

• The company's ability to continue as a going concern is uncertain, requiring additional funding.
• The company is subject to risks associated with completing clinical trials and obtaining regulatory approvals.
• The company is dependent on a limited number of third parties for manufacturing and license rights.
• The company faces competition from other products and must protect its intellectual property.
• The company's commercial prospects may be harmed if third-party labs generate virologic data that creates doubt regarding the neutralization activity of its product candidates.
• The company is dependent on third parties to conduct clinical trials and if those third parties do not perform satisfactorily, the company may not be able to obtain or maintain regulatory authorization or approval or successfully commercialize product candidates.

Future Outlook

The company expects preliminary data readouts from the Phase 1 clinical trial of VYD2311 late in the fourth quarter of 2024 and anticipates additional clinical readouts from the VYD2311 program throughout 2025. The company also plans to leverage its INVYMAB platform to develop new mAb candidates for COVID-19 and other viral diseases.

Management Comments

• The company is focused on antibody discovery and use of Adimabs platform technology while building its own internal capabilities.
• The company aims to develop a continuous repertoire of SARS-CoV-2 neutralizing mAbs to keep pace with viral evolution.
• The company is actively pursuing additional funding through various means to support its operations and growth strategy.

Industry Context

The company operates in the biopharmaceutical industry, focusing on developing treatments for infectious diseases, particularly COVID-19. The company's approach of using a platform to rapidly develop new antibodies is aligned with the need for adaptable treatments in the face of evolving viral threats. The company is also leveraging its existing partnerships and building internal capabilities to support its research and development efforts.

Comparison to Industry Standards

• Invivyd's approach to rapidly develop new monoclonal antibodies using its INVYMAB platform is similar to other companies that are focused on developing adaptable treatments for infectious diseases.
• The company's reliance on third-party contract manufacturers and research organizations is a common practice in the biopharmaceutical industry, particularly for smaller companies.
• The company's financial results, including its net losses and cash burn, are typical for a clinical-stage biopharmaceutical company that is investing heavily in research and development.
• The company's focus on COVID-19 treatments is aligned with the ongoing global health concern, but it also faces competition from other companies developing similar treatments.
• The company's decision to pursue an immunobridging pathway for future EUAs is a strategic move to expedite the development and approval of new mAb candidates, which is a common approach in the industry.

Legal Proceedings

• A securities class action lawsuit against the company and certain former officers was dismissed in its entirety with prejudice and without leave to amend.

Related Party Transactions

• The company has ongoing transactions with Adimab, including milestone and royalty payments, and payments for services.
• The company had transactions with Population Health Partners, L.P. (PHP), a related party, which terminated in July 2024.

Stakeholder Impact

• Shareholders face the risk of dilution from potential equity offerings and the uncertainty of the company's ability to continue as a going concern.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company fails to secure additional funding.
• Customers (healthcare providers and patients) may be affected by the availability and pricing of PEMGARDA and future product candidates.
• Suppliers and creditors may be impacted by the company's financial instability and potential inability to meet its obligations.

Next Steps

• The company expects preliminary data readouts from the Phase 1 clinical trial of VYD2311 late in the fourth quarter of 2024.
• The company anticipates additional clinical readouts from the VYD2311 program throughout 2025.
• The company will continue to pursue additional funding through various means.
• The company will continue to monitor SARS-CoV-2 variants and their impact on its product candidates.

Key Dates

Keywords

PEMGARDA, VYD2311, COVID-19, monoclonal antibodies, mAb, clinical trials, emergency use authorization, EUA, immunocompromised, biopharmaceutical, research and development, manufacturing, regulatory approval, INVYMAB platform